This guidance has been updated and replaced by NICE's technology appraisal guidance on nusinersen and risdiplam for treating spinal muscular atrophy (TA1162).
This guidance has been updated and replaced by NICE's technology appraisal guidance on nusinersen and risdiplam for treating spinal muscular atrophy (TA1162).